clinical trial to study the comparative effect of a classical unani antiobesity drug safoof-e-muhazzil on hyperlipidemia in its classical powder form and in compressed tablet form

CLINICAL STUDY ON HYPERLIPIDEMIA AND COMPARATIVE EVALUATION OF EFFICACY OF A COMPOUND UNANI FORMULATION (SAFOOF-E-MUAHAZZIL) AND COMPRESSED TABLET OF SAFOOF-E-MUHAZZIL IN ITS MANAGEMENT

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/06/001825

Enrollment

Registered

2011-06-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: safoof muhazzil: 5gms twice daily for six weeks orally Control Intervention1: compressed tablet of safoof muhazzil: 5tablets(equivalent to 5gms together) twice daily for six weeks orall

Eligibility

Inclusion criteria

Inclusion criteria: Person aged 20 - 70 Years M/F Patients willing to sign consent form & participate in Clinical Trial voluntarily. Hyperlipidemic

Exclusion criteria

Exclusion criteria: Persons below 20 yrs and Above 70 yrs of age Pregnancy Liver diseases Renal diseases Diabetes mellitus Type II Alcoholic AIDS Thyroid Disease Drug intake ? Corticosteroids, Diuretics, Beta-blockers, Oral contraceptives, Cyclosporin, Androgens & Retinoids

Design outcomes

Primary

Measure	Time frame
hyperlipidemiaTimepoint: 0,2,4, and 6 weeks	—

Secondary

Measure	Time frame
obesity, hypertensionTimepoint: 0,2,4, and 6 weeks	—

Countries

India

Contacts

Public ContactDrumar jahangir

asim_jhamdard@yahoo.in9811794448

Outcome results